Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Nov;85(11):2634-2637.
doi: 10.1111/bcp.14097. Epub 2019 Sep 12.

Methylphenidate and stuttering

Thierry Trenque  1   2 , Gwladys Claustre  1 , Emmanuelle Herlem  1 , Zoubir Djerada  1 , Agathe Trenque  1 , Aurore Morel  1 , Brahim Azzouz  1   2
Affiliations

Methylphenidate and stuttering

Thierry Trenque et al. Br J Clin Pharmacol. 2019 Nov.

Abstract

Methylphenidate (MPH) is a piperidine similar to amphetamines, and is indicated for attention deficit hyperactivity disorder. Studies concerning stuttering occurring with MPH are contradictory. We investigated the association between MPH and stuttering. We analysed reports in the World Health Organization global individual case safety reports database, Vigibase, up to 31 December 2018, with the MedDRA preferred term “dysphemia” and the lower level terms “stutter” and “stuttering”. The association between exposure to MPH and occurrence of the adverse drug reaction was estimated by disproportionality analysis. Reporting odds ratios (RORs) were calculated with 95% confidence intervals (CIs). In total, 2975 cases of dysphemia were reported, of which 46 reports were associated with MPH. For the Preferred Term “dysphemia”, the ROR was 7.3 (95% CI: 5.4-9.8). With the Lower Level Term “stuttering”, 584 cases were registered in the database of which 17 involved MPH. The ROR was 13.9 (95% CI: 8.6-22.5). This study found a signal for stuttering with MPH.

Keywords: Vigibase; methylphenidate; stuttering.

PubMed Disclaimer

Conflict of interest statement

There are no competing interests to declare.

References

    1. Sharma A, Couture J. A review of the pathophysiology, etiology, and treatment of attention‐deficit hyperactivity disorder (ADHD). Ann Pharmacother. 2014;48(2):209‐225. - PubMed
    1. Thomas R, Sanders S, Doust J, Beller E, Glasziou P. Prevalence of attention‐deficit/hyperactivity disorder: a systematic review and meta‐analysis. Pediatrics. 2015;135(4):e994‐e1001. - PubMed
    1. Metzger FL, Auer T, Helms G, et al. Shifted dynamic interactions between subcortical nuclei and inferior frontal gyri during response preparation in persistent developmental stuttering. Brain Struct Funct. 2018;223(1):165‐182. - PMC - PubMed
    1. Perez HR, Stoeckle JH. Stuttering: clinical and research update. Can Fam Physician. 2016;62(6):479‐484. - PMC - PubMed
    1. Devroey D, Beerens G, Van De Vijver E. Methylphenidate as a treatment for stuttering: a case report. Eur Rev Med Pharmacol Sci. 2012;16(Suppl 4):66‐69. - PubMed

Substances